Expression of C-X-C chemokine receptor type 7 in otorhinolaryngologic neoplasms

Tang, Tian; Xia, Qing; Qiao, Xiaoming; Xi, Mingrong

doi:10.11622/smedj.2016057

Cited by 5 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides CXCR4, CXCR7 has also been found to bind to CXCL12 with high affinity [15–16]. CXCR7 is now classified as a chemokine co-receptor, together with CXCR4, for CXCL12 and C-X-C motif chemokine I-TAC (CXCL11)[17–18]. Similar to CXCL12, CXCR4 is also widely detected in the central nervous systems, neural stem cells, liver oval/stem cells, CD34+ hematopoietic progenitor cells, white blood cells [19], primordial germ cells, skeletal muscle satellite progenitor cells, as well as intestinal epithelium [20].…”

Section: Introductionmentioning

confidence: 99%

Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy

Zhou

Guo

Liu

et al. 2019

CMC

195

143

View full text Add to dashboard Cite

Chemokines, which have chemotactic abilities, are comprised of over 50 family members. Through binding to the 7-transmembrane domain of G-protein-coupled receptors (GPCR), they function in immune cells by trafficking and regulating cell prolif¬eration, differentiation, activation, and migration, homing under both physiologic and pathologic conditions. The alpha-chemokine receptor CXCR4 for the alpha-chemokine stromal cell-derived-factor-1 (SDF-1) is most widely expressed by tumors. CXCL12/CXCR4 axis is a major culprit for human tumor because of its crucial role in tumor initiation and progression by activating a number of signaling pathways, such as ERK1/2, ras, PLC/ MAPK, p38 MAPK, and SAPK/ JNK, as well as regulating cancer stem cells. CXCL12/CXCR4 antagonists have been developed, which have shown promising results in both in vitro and in vivo anti-cancer activity in several tumor types. This review provides an evaluation of CXCL12/CXCR4 as a potential therapeutic target for human tumors; it also focuses on the synergistic effects of inhibition of CXCL12/CXCR4 axis and immunotherapy as well as chemotherapy. Together, CXCL12/CXCR4 axis can be a potential therapeutic target for tumors and used with immunotherapy for additive effects.

show abstract

Section: Introductionmentioning

confidence: 99%

Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy

Zhou

Guo

Liu

et al. 2019

CMC

195

143

View full text Add to dashboard Cite

show abstract

“…A previous study demonstrated that CXC chemokine-7 inhibits growth and migration of oral tongue squamous cell carcinoma cells, mediated by the epithelial-mesenchymal transition signaling pathway the CXCR-7 gene encodes members of the G protein-coupled receptor family, which was identified as an orphan receptor for vasoactive intestinal peptides (13). CXCR-7 is now classified as a novel receptor for the CXC motif chemokine 12/stromal cell-derived factor 1-alpha, which may serve a role in the progression, metastasis and angiogenesis of otorhinolaryngologic tumors (14). In addition, CXCR-7 has been considered to serve an essential role in the pathogenesis of tumor angiogenesis and metastasis (11).…”

Section: Introductionmentioning

confidence: 99%

CXC chemokine-7 inhibits growth and migration of oral tongue squamous cell carcinoma cells, mediated by the epithelial-mesenchymal transition signaling pathway

Liu

Guo

2017

Molecular Medicine Reports

View full text Add to dashboard Cite

Oral tongue squamous cell carcinoma (OTSCC) is the most common oral malignancy with different histopathological symptoms and etiology of tumorigenesis. Migration and invasion is the most important characteristics of OTSCC, and limits tumor therapy in clinics. The epithelial‑to‑mesenchymal transition (EMT) signaling pathway is an important process in the progress of tumor cell migration and invasion. Previous studies have indicated that C‑X‑C chemokine receptor‑7 (CXCR‑7) promotes the progression and metastasis of tumor cells, presenting a potential target molecule for cancer therapy. The present study investigated the inhibitory effects of C‑X‑C chemokine‑7 (CXC‑7) on human OTSCC cells both in vitro and in vivo. The results demonstrated that the Tca8113 human OTSCC cell line expressed higher levels of CXC‑7 mRNA compared with the hNOE human normal oral epithelial cell line. MTT assays indicated that CXC‑7 suppressed Tca8113 cell growth, and the cytotoxicity of CXC‑7 was indicated as the cell survival of the negative control group was significantly decreased compared with the blank control and hNOE cells. Migration and invasion assays revealed that CXC‑7 inhibited Tca8113 cell local expansion and distant metastasis. In addition, the results demonstrated that the extracellular signal‑regulated kinase (ERK)/protein kinase B (AKT) signaling pathway was inhibited after CXC‑7 treatment in Tca8113 cells. N‑cadherin, E‑Cadherin, Snail and Slug expression levels in the ERK/AKT signaling pathway were inhibited in Tca8113 cells after treatment with CXC‑7. It was demonstrated that important extracellular matrix proteins involved in cell migration, including Slug, collagen type I and Vimentin, were significantly downregulated by CXC‑7 treatment. In conclusion, CXC‑7 inhibited growth and migration in OTSCC cells, mediated by the EMT signaling pathway. This suggests that CXC‑7 serves an inhibitory role in OTSCC migration, implicating CXCR‑7 as a promising biomarker for chemokine receptor‑based drug development.

show abstract

“…Hypoxic preconditions induce the expression of CXCR7 mRNA in squamous epithelial cervical carcinoma cells, which resemble bone marrow–derived mesenchymal stem cells. Moreover, the high expression of CXCR7 in malignant tumors may be due to hypoxia; this finding has been confirmed by several studies 3. Second, CXCR7 might participate in the formation of (and angiogenesis in) CSCC because CXCR7 is strongly expressed in tumor-associated blood vessels in breast and prostate cancer tissues 11,12.…”

Section: Discussionmentioning

confidence: 64%

<p>CXCR7, a Prognostic Biomarker in Cervical Squamous Cell Carcinoma, May Be a Screening Index for Treatment Options at Stages IB1 and IIA1</p>

Zhao

Qin²,

Zhao

et al. 2019

CMAR

View full text Add to dashboard Cite

PurposeRecent studies indicate that CXC chemokine receptor type 7 (CXCR7) is associated with tumorigenesis, progression, and metastasis of various cancers, but its roles and molecular mechanisms of action in cervical squamous cell carcinoma (CSCC) remain unclear. Our purpose was to explore the expression patterns of CXCR7 and epidermal growth factor receptor (EGFR) in CSCC and to identify possible correlations with clinical characteristics. We also tested whether CXCR7 can be a screening index for treatment options for CSCC stages IB1 and IIA1.MethodsExpression of CXCR7 and EGFR in tumors from 165 patients with CSCC was evaluated by immunohistochemistry and compared with the clinical data including survival.ResultsPatients at CSCC stages IB1 and IIA1 received different treatment options, including radical hysterectomy, pelvic lymph node dissection, and para-aortic lymph node sampling (RH group, 67 patients) or pelvic external-beam radiation therapy with brachytherapy (EBRT group, 34 patients). Disease-free survival (DFS) and overall survival (OS) were compared between two groups at different CXCR7 expression levels. Immunohistochemical staining showed that CXCR7, EGFR, phospho-ERK, and phospho-AKT amounts increased from normal cervical epithelia and cervical intraepithelial neoplasia to CSCC, and CXCR7 was associated with the disease stage, lymph node metastasis, tumor size ≥40 mm, and EGFR expression. Kaplan–Meier analysis revealed that CXCR7 and EGFR expression was associated with shorter DFS and OS. Multivariate analysis suggested that CXCR7 was independently associated with DFS and OS. Prevalence of recurrence and distant metastasis was significantly lower in the EBRT group than in the RH group during CXCR7 expression. Besides, CXCR7 knockdown significantly decreased the proliferation and invasion of CSCC cells.ConclusionCXCR7 is coexpressed with EGFR, which may be involved in ERK or AKT pathway activation. CXCR7 may be a screening index for treatment options at CSCC stages IB1 and IIA1.

show abstract

Expression of C-X-C chemokine receptor type 7 in otorhinolaryngologic neoplasms

Abstract: CONCLUSION CXCL12 and its receptor CXCR7 may contribute to eosinophilic inflammation in patients with chronic sinusitis and nasal polyps. Our results also suggest that CXCR7 may play a role in the progression, metastasis and angiogenesis of otorhinolaryngologic tumours.

Cited by 5 publications

References 20 publications

Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy

Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy

CXC chemokine-7 inhibits growth and migration of oral tongue squamous cell carcinoma cells, mediated by the epithelial-mesenchymal transition signaling pathway

<p>CXCR7, a Prognostic Biomarker in Cervical Squamous Cell Carcinoma, May Be a Screening Index for Treatment Options at Stages IB1 and IIA1</p>

Contact Info

Product

Resources

About